ICON Announces Executive Leadership Transition
20 Outubro 2016 - 6:15AM
Business Wire
- Mr. Ciaran Murray to transition to
Chairman, effective 1st March 2017
- Dr. Steve Cutler to be appointed Chief
Executive Officer, effective 1st March 2017
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that,
as part of its planned succession of executive leadership, Mr.
Ciaran Murray will transition to the role of Chairman of the Board
of Directors and Dr. Steve Cutler will be appointed as Chief
Executive Officer, with both changes effective as of 1st March
2017.
Dr. Cutler joined ICON in 2011 as President, ICON Clinical
Research Services. He was promoted to ICON plc Chief Operating
Officer in January 2014 and was appointed to the Board of Directors
in November 2015. “Steve will bring significant industry experience
and proven leadership capabilities to the role of Chief Executive
Officer,” said Mr. Declan McKeon, acting Chairman of the Board. “As
Chief Operating Officer, Steve has strengthened and expanded our
global operations and he is well placed to lead the company to
continued growth and success. The Board is happy to have such a
strong internal successor to take over from Ciaran now that he has
decided to transition to the role of chairman.”
Commenting on his appointment Dr. Cutler added, “I am pleased
and excited to be appointed as ICON’s Chief Executive Officer. I
look forward to continuing to work with Ciaran and the rest of the
Board during the transition period and beyond. ICON has a strong
management team and together we will remain focused on enhancing
our position as the CRO partner of choice in drug development.
Also, I would like to personally thank Ciaran for his leadership of
ICON over the last five years.”
Prior to joining ICON, Dr. Cutler was Chief Executive Officer of
Kendle. Prior to Kendle, Dr. Cutler held various senior roles in
both Quintiles and Sandoz (now Novartis). Dr. Cutler holds a B.Sc.
and a Ph.D from the University of Sydney and a Masters of Business
Administration from the University of Birmingham (UK).
Mr. McKeon also thanked Mr. Murray for his leadership of the
company. “Since 2011, Ciaran has led ICON through a transformative
phase of our development which has seen the company deliver
outstanding financial and operational performance and broaden its
strategic capabilities. Ciaran has also been an excellent partner
for the Board and we are delighted that he has accepted our offer
to transition to the role of Chairman of the Board of
Directors.”
Mr. Murray commented, “The last five years as ICON’s CEO have
been the most exciting and fulfilling of my professional career.
Since I took over as Chief Executive Officer, five years ago the
company has made significant progress. Through our focus on
innovation, investment in talent and by continuing to enhance and
broaden our service capabilities we have driven significant growth
and shareholder value. During this time, we have developed a strong
management team and with ICON well positioned for the future the
time is right for me to step down as Chief Executive Officer and
for Steve to take over leadership of ICON. I look forward to
continuing to work with Steve and the rest of the Board in my new
role as Chairman.”
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 88 locations in 37 countries and has approximately
12,600 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161020005558/en/
ICON plcInvestor Relations, 1-888-381-7923orBrendan Brennan,
+353-1-291-2000Chief Financial OfficerorSimon Holmes,
+353-1-291-2000EVP Investor Relations and Corporate Development
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024